Q3 2025 · 13F-HR
Vivo Capital, LLCholdings as filed
Filed 2025-11-14 · accession 0001213900-25-110767
$1.24B
Reported value
47
Positions
2025-09-30
Period end
The Brief · Vivo Capital, LLC · Q3 2025
AI · grounded in 13F
Vivo Capital, LLC established a new position in Soleno Therapeutics Inc SLNO valued at $154M. The fund also initiated new stakes in Verona Pharma PLC VRNA for $148.7M and Cidara Therapeutics, Inc. CDTX for $125.6M. Additional new positions include Terns Pharmaceuticals Inc 430 and Trevi Therapeutics Inc TRVI.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 834203309 | SLNO | Soleno Therapeutics Inc | $154.0M | 12.4% | 2,278,203 | Common | SOLE |
| 925050106 | VRNA | Verona Pharma PLC | $148.7M | 12.0% | 1,393,432 | Common | SOLE |
| 171757206 | CDTX | Cidara Therapeutics, Inc. | $125.6M | 10.1% | 1,311,425 | Common | SOLE |
| 880881107 | 430 | Terns Pharmaceuticals Inc | $51.8M | 4.17% | 6,895,746 | Common | SOLE |
| 89532M101 | TRVI | Trevi Therapeutics Inc | $46.6M | 3.75% | 5,094,668 | Common | SOLE |
| G29687103 | AVDL | Avadel Pharmaceuticals PLC | $41.0M | 3.30% | 2,684,109 | Common | SOLE |
| 19240Q201 | COGT | Cogent Biosciences Inc | $40.1M | 3.22% | 2,789,137 | Common | SOLE |
| P8696W104 | SVA | Sinovac Biotech Ltd. | $38.2M | 3.07% | 5,903,000 | Common | SOLE |
| 68622P109 | ORIC | Oric Pharmaceuticals Inc | $37.5M | 3.02% | 3,126,604 | Common | SOLE |
| 374163103 | GERN | Geron Corp | $37.3M | 3.00% | 27,225,292 | Common | SOLE |
| 20454B104 | CMPX | Compass Therapeutics Inc | $33.4M | 2.69% | 9,545,466 | Common | SOLE |
| 26818M108 | DYN | Dyne Therapeutics Inc | $33.1M | 2.66% | 2,614,960 | Common | SOLE |
| 00370M103 | ABVX | Abivax SA - ADR | $30.5M | 2.45% | 359,305 | Common | SOLE |
| 10919W405 | DRUG | Bright Minds Biosciences Inc | $30.4M | 2.45% | 501,617 | Common | SOLE |
| 89157D105 | TRML | Tourmaline Bio Inc. | $28.3M | 2.28% | 591,882 | Common | SOLE |
| 98937L105 | ZBIO | Zenas Biopharma Inc | $26.3M | 2.11% | 1,183,260 | Common | SOLE |
| 92337C203 | VSTM | Verastem Inc | $23.4M | 1.88% | 2,644,985 | Common | SOLE |
| 78397T202 | SABS | SAB Biotherapeutics Inc | $23.0M | 1.85% | 11,420,000 | Common | SOLE |
| 92790C104 | VRDN | Viridian Therapeutics Inc | $21.2M | 1.71% | 982,576 | Common | SOLE |
| 00973Y108 | AKRO | Akero Therapeutics Inc | $20.6M | 1.66% | 434,689 | Common | SOLE |
| 29479A108 | ERAS | Erasca Inc | $20.2M | 1.63% | 9,273,428 | Common | SOLE |
| 76200L309 | RZLT | Rezolute Inc | $19.9M | 1.60% | 2,112,432 | Common | SOLE |
| 00461U105 | ACRS | Aclaris Therapeutics, Inc. | $16.9M | 1.36% | 8,888,888 | Common | SOLE |
| 221015100 | CRVS | Corvus Pharmaceuticals Holdings | $16.5M | 1.33% | 2,234,566 | Common | SOLE |
| 68062P106 | OLMA | Olema Pharmaceuticals Inc | $14.7M | 1.19% | 1,505,862 | Common | SOLE |
| 252828108 | DNTH | Dianthus Therapeutics Inc | $13.9M | 1.12% | 353,998 | Common | SOLE |
| 50180M108 | LBRX | LB Pharmaceuticals Inc | $12.6M | 1.02% | 800,000 | Common | SOLE |
| 13463J101 | CAMP | CAMP4 Therapeutics Inc | $11.8M | 0.95% | 3,921,568 | Common | SOLE |
| 04635X102 | CATBUSD | Astria Therapeutics Inc | $11.3M | 0.91% | 1,552,685 | Common | SOLE |
| 713317105 | PEPG | Pepgen Inc | $10.7M | 0.86% | 2,325,000 | Common | SOLE |
| 23306J309 | DBVT | DBV Technologies SA | $10.5M | 0.85% | 1,054,506 | Common | SOLE |
| 74006W207 | PRAX | Praxis Precision Medicines | $10.5M | 0.85% | 198,895 | Common | SOLE |
| 00289Y206 | ABEO | Abeona Therapeutics, Inc. | $9.7M | 0.78% | 1,842,751 | Common | SOLE |
| 23284F105 | CTMX | Cytomx Therapeutics Inc | $9.2M | 0.74% | 2,884,615 | Common | SOLE |
| 29842P105 | EPRX | Eupraxia Pharmaceuticals Inc | $8.0M | 0.64% | 1,350,000 | Common | SOLE |
| 90466Y202 | UNCY | Unicycive Therapeutics | $7.8M | 0.63% | 1,789,916 | Common | SOLE |
| 61023L207 | MNPR | Monopar Therapeutics Inc | $7.4M | 0.59% | 90,500 | Common | SOLE |
| 87583X109 | TNGX | Tango Therapeutics Inc | $6.5M | 0.53% | 776,699 | Common | SOLE |
| 24661P807 | DCTH | Delcath Systems, Inc. | $6.1M | 0.49% | 569,526 | Common | SOLE |
| 82686Q101 | SLN | Silence Therapeutics PLC | $5.7M | 0.46% | 1,105,454 | Common | SOLE |
| 282559103 | ETNBGBP | 89Bio Inc | $5.5M | 0.45% | 376,804 | Common | SOLE |
| 45783C200 | TIL | Instil Bio Inc | $5.2M | 0.42% | 292,743 | Common | SOLE |
| 81749D107 | SERA | Sera Prognostics Inc | $5.1M | 0.41% | 1,650,440 | Common | SOLE |
| 86889P208 | SRZN | Surrozen Inc | $3.4M | 0.27% | 260,000 | Common | SOLE |
| 88032L605 | TENX | Tenax Therapeutics Inc | $1.6M | 0.13% | 208,333 | Common | SOLE |
| 097702203 | BOLT | Bolt Therapeutics Inc | $936,660 | 0.08% | 176,064 | Common | SOLE |
| 74019P207 | DTIL | Precision Biosciences Inc | $25,806 | 0.00% | 4,675 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.